Gamida rises on positive data from blood cancer therapy study

Gamida Cell

29/09/2022 16:08

** U.S.-listed shares of Israeli biotech firm Gamida Cell
 GMDA.O  rise 7% to $1.74 in morning trade after co reports
positive data from late-stage trial of its experimental blood
cancer therapy  urn:newsml:reuters.com:*:nBwwRxmca
    ** Long-term data from trial shows cell therapy Omidubicel
has an overall survival rate of 63% and a disease-free survival
rate of 56% three years after getting the experimental treatment
- co
    ** Follow-up data shows sustained long-term bone marrow
recovery 10 years after treatment - co
    ** All six brokerages covering GMDA rate the stock "buy" or
higher; their median PT is $15
    ** Including session gains, stock down 32% YTD
 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))